Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10299MR)

This product GTTS-WQ10299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10299MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3893MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ14066MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ3085MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ3133MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ861MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ2097MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ2584MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ3934MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW